January 29, 2018 / 9:25 PM / a month ago

BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint

Jan 29 (Reuters) - Corbus Pharmaceuticals Holdings Inc :

* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT

* ‍FDA ALSO AGREED TO INCLUSION OF ADOLESCENTS 12-17 YEARS OF AGE ALONGSIDE ADULTS IN PHASE 2B STUDY​

* ‍FIRST PATIENT EXPECTED TO BE DOSED IN THE QUARTER FOR PHASE 2B CYSTIC FIBROSIS STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below